buprenorphine/naloxone sublingual film / Generic mfg. - LARVOL DELTA

Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments (clinicaltrials.gov) - P2/3 | N=658 | Recruiting | Sponsor: University of British Columbia | Trial completion date: Jun 2027 ➔ Jun 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Substance Abuse

Case Report: Pharmacist-Led Induction of Sublingual Buprenorphine/Naloxone for Kratom Use Disorder. (PubMed, J Psychoactive Drugs) - "The pain CPP led, planned, and performed the induction of buprenorphine/naloxone and frequently followed up with the patient to reassess his symptoms. The buprenorphine/naloxone, along with other pharmacologic and nonpharmacologic treatments, successfully managed his pain and other symptoms without significant withdrawal or return of cravings."

Journal • Addiction (Opioid and Alcohol) • Back Pain • Musculoskeletal Pain • Pain

An Unrecognized Cause of Chronic Diarrhea: Opioid-Induced Adrenal Insufficiency - A Case Report. (PubMed, J Pain Palliat Care Pharmacother) - "Hydrocortisone therapy resulted in rapid hemodynamic improvement and resolution of gastrointestinal symptoms. Chronic gastrointestinal complaints are not always gastrointestinal in origin and should prompt consideration of endocrine etiologies, particularly in patients with opioid exposure."

Journal • Cardiovascular • Endocrine Disorders • Heart Failure • Hypotension • Nephrology • Pain • Renal Disease

Over-the-Counter but Not Benign: Perioperative Kratom Withdrawal From Easily Accessible Convenience Store Supplements (ASA 2026) - "He was discharged on Suboxone with an addiction psychiatry follow-up. As novel supplements become increasingly accessible, patients may not recognize their clinical significance. This case highlights the importance of comprehensive substance histories to anticipate withdrawal and reduce perioperative complications."

Cardiovascular • CNS Disorders • Hypertension

Understanding the Patient and Physician Experience with Buprenorphine/Naloxone Sublingual Film for Patients with Chronic Pain Who Do Not Have an Opioid Use Disorder: A Qualitative Study in the Post-X-Waiver Era (ASA 2026) - "Abstract is embargoed at this time."

Clinical • Addiction (Opioid and Alcohol) • Pain • Substance Abuse

"Methadone at the pharmacy like Suboxone®?… It would untangle a lot of tangles." Perspectives of North Carolinians with lived experience of opioid use on potential benefits of methadone dispensing at community pharmacies. (PubMed, Subst Use Misuse) - "Participants perceived benefits of pharmacy methadone dispensing that they anticipated would address known OTP barriers, such as stigma, lack of privacy, limited dosing hours, lack of access following climate events, such as hurricanes, and ability to switch back to methadone from buprenorphine if desired. PWLLE anticipated that pharmacy dispensing of methadone would likely increase privacy and convenience in MOUD access, compared to OTPs, particularly for rural U.S. patients."

Journal • Addiction (Opioid and Alcohol) • Substance Abuse

Impact of a Pharmacist-Led Telehealth Intervention on Medication Adherence for Patients with Substance Use Disorder in a Rural Community Pharmacy. (PubMed, Innov Pharm) - "A majority of these patients were being treated for opioid use disorder and were taking suboxone... The implementation of a pharmacist-led intervention of support services for patients with substance use disorder improved medication adherence. The pharmacists were able to address additional issues such as side effects, social determinants of health, and medication cost at these telehealth appointments."

Journal • Substance Abuse

OUTLAST-B: Opioid Use Disorder Treatment Linkage at Strategic Touchpoints Using Buprenorphine (clinicaltrials.gov) - P2/3 | N=373 | Completed | Sponsor: Friends Research Institute, Inc. | Enrolling by invitation ➔ Completed | Trial primary completion date: Jul 2025 ➔ Jan 2026

Trial completion • Trial primary completion date • Substance Abuse

EASE: Examining Analgesic Synergy and Efficacy in Trauma Care (clinicaltrials.gov) - P4 | N=282 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Sep 2026 ➔ Dec 2026 | Initiation date: May 2026 ➔ Aug 2026 | Trial primary completion date: Sep 2026 ➔ Dec 2026

Trial completion date • Trial initiation date • Trial primary completion date • Mood Disorders • Pain • Substance Abuse

Comparing Opioid and Benzodiazepine Discourse on Reddit: A Corpus-Based NLP Study of Recovery and Harm-Reduction (APA 2026) - "In contrast, r/benzodiazepines discourse centered on tapering and seizure avoidance, with brand-specific drug talk (clonazepam, diazepam, valium) and "dose-math" language (mg, percent, cut)...High-engagement "micro-genres" included scare stories ("friend took multiple Suboxone pills"), myth-busting posts (about methadone or precipitated withdrawal), and urgent taper pleas; each reliably generated >130 comments... Reddit drug forums show distinct rhetorical ecologies: opioid discussions mix moral identity with practical medication-assisted treatment debates, whereas benzodiazepine discussions foreground taper mechanics and seizure risk. These insights highlight opportunities for tailored digital interventions: reframing "being on subs" as already clean, embedding taper-planning tools, and timing peer-support prompts to align with community rhythms. Social media forums can serve as real-time ethnographies of drug use and recovery,..."

Addiction (Opioid and Alcohol) • CNS Disorders • Epilepsy

Preparedness and Perceptions: Third-year Medical Students' Understanding of Harm Reduction and Medication for Opioid Use Disorder (APA 2026) - "Harm reduction offers a pragmatic, evidence-based approach to mitigating adverse outcomes associated with opioid use disorder (OUD), including strategies such as naloxone distribution, fentanyl test kits, syringe exchange programs, "Never Use Alone" hotlines, and medication for opioid use disorder (MOUD)...96%, 87%, 59%, and 54% of respondents (n=101) were familiar with methadone, naltrexone, suboxone, and extended-release buprenorphine (e.g. Brixadi, Sublocade), respectively... Results showed that 80% of respondents (n=104) had clinical exposure to patients with OUD. 13.6% of respondents (n=104) felt adequately prepared to treat OUD patients. 96%, 87%, 59%, and 54% of respondents (n=101) were familiar with methadone, naltrexone, suboxone, and extended-release buprenorphine (e.g."

Addiction (Opioid and Alcohol) • Human Immunodeficiency Virus • Infectious Disease • Substance Abuse

Circulating plasma protein biomarkers associated with risk of negative clinical outcomes in virally suppressed people with HIV receiving medications for opioid use disorder. (PubMed, Front Mol Biosci) - "To address this knowledge gap, we sought to identify immune biomarkers in virally suppressed PWH on medications for opioid use disorder (MOUD), including methadone (MET) and suboxone (SUB), and to assess possible associations with clinical outcomes. The increased risks for kidney disease and dementia were confirmed using beta regression analysis. These data suggest that PWH chronically exposed to MOUD have higher levels of circulating protein biomarkers that may be linked to increased risk of adverse clinical outcomes."

Biomarker • Clinical data • Journal • Addiction (Opioid and Alcohol) • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Congestive Heart Failure • Dementia • Heart Failure • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Nephrology • Renal Disease • Substance Abuse • CXCL12 • IGLL1 • ROR1

Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients (clinicaltrials.gov) - P4 | N=4 | Terminated | Sponsor: Theresa Jacob, PhD, MPH | Phase classification: P=N/A ➔ P4

Phase classification • Addiction (Opioid and Alcohol) • Pain • Substance Abuse

Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (clinicaltrials.gov) - P4 | N=12 | Recruiting | Sponsor: Pouya Azar | Not yet recruiting ➔ Recruiting

Enrollment open • Substance Abuse

AMOHI-1: Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1 (clinicaltrials.gov) - P2 | N=78 | Terminated | Sponsor: University of Pennsylvania | N=225 ➔ 78 | Recruiting ➔ Terminated; Funding not renewed

Enrollment change • IO biomarker • Trial termination • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Substance Abuse • CD4

Development and evaluation of machine learning models for the detection of emergency department patients with opioid misuse from clinical notes. (PubMed, JAMIA Open) - "Explainability analyses showed the most predictive terms were "heroin," "opioids," "alcoholic intoxication, chronic," "cocaine," "opiates," and "suboxone." NLP-based models perform comparably to entry of ICD-10-CM diagnosis codes for the detection of ED encounters with opioid misuse. Fine tuning with domain adaptation for pre-trained language models resulted in improved performance."

Journal • Substance Abuse

Patient perspectives on buprenorphine/naloxone for chronic noncancer pain: A qualitative interview study. (PubMed, Can J Pain) - "Buprenorphine/naloxone (Suboxone) is an emerging option for chronic noncancer pain (CNCP), but evidence on transitioning patients from full opioid agonists remains limited...Side effects were tolerable, and most would recommend the treatment. Improved communication during transitions may enhance patient experiences."

Interview • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Oncology • Pain

Aortic Elasticity and Cardiac Electrophysiological Balance in Opioid Users Receiving Buprenorphine/Naloxone Maintenance Therapy. (PubMed, Biomedicines) - "This study investigated aortic stiffness and distensibility in individuals receiving buprenorphine/naloxone (Suboxone), and examined their associations with echocardiographic and electrocardiographic parameters, including the index of cardiac electrophysiological balance (iCEB and iCEBc)... Chronic buprenorphine/naloxone therapy appears to be associated with changes in aortic elasticity, blood pressure, and mild electrophysiological alterations. These results support the use of non-invasive vascular and electrocardiographic evaluations for cardiovascular risk monitoring and stratification among patients receiving opioid maintenance therapy."

Journal • Addiction (Opioid and Alcohol) • Cardiovascular

When Safe Becomes Deadly: Loperamide-Induced Torsades de Pointes (SCCM 2026) - "She was discharged safely on Suboxone therapy for Opioid Use Disorder. Loperamide overdose leads to severe cardiac toxicity due to its potent blockade of sodium and hERG potassium channels, resulting in prolonged QT intervals and life-threatening TdP. Clinicians should maintain high suspicion for loperamide misuse in unexplained arrhythmias. Artificial intelligence was utilized to support the drafting of the abstract in the preparation of this case report."

Addiction (Opioid and Alcohol) • Cardiovascular • CNS Disorders • Infectious Disease • Metabolic Disorders • Pneumonia • Respiratory Diseases • Substance Abuse

INDV-6001 Multiple-Dose Pharmacokinetic Study (clinicaltrials.gov) - P2 | N=123 | Completed | Sponsor: Indivior Inc. | Active, not recruiting ➔ Completed

Trial completion • Substance Abuse

NEONATAL QTC PROLONGATION ASSOCIATED WITH PRENATAL BUPRENORPHINE-NALOXONE EXPOSURE (ACC 2026) - "OUD is increasing and Suboxone is a treatment option in pregnancy. This case highlights a possible link between QTc prolongation in an infant and intrauterine exposure to Suboxone warranting further study."

Cardiovascular • Substance Abuse

COPILOT: Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation (clinicaltrials.gov) - P4 | N=50 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Substance Abuse

EASE: Examining Analgesic Synergy and Efficacy in Trauma Care (clinicaltrials.gov) - P4 | N=282 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences

New P4 trial • Mood Disorders • Pain • Substance Abuse

Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (clinicaltrials.gov) - P4 | N=12 | Not yet recruiting | Sponsor: Pouya Azar

New P4 trial • Substance Abuse

Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: Massachusetts General Hospital | N=60 ➔ 0 | Trial completion date: Dec 2022 ➔ Dec 2025 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Dec 2022 ➔ Dec 2025

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Pain